We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Methotrexate in the treatment of cancer; report of the proceedings of a symposium at the Royal Society of Medicine, 18 September, 1961, sponsored by Lederle Laboratories, a Division of Cyanamid of Great Britain, Ltd

Warren N. Bell, MD
JAMA. 1963;185(4):336. doi:10.1001/jama.1963.03060040120055.
Text Size: A A A
Published online


This book is a composite of a group of papers presented at a symposium of the Royal Society of Medicine on Sept 18, 1961. It opens with a review of the biochemistry and pharmacology of methotrexate and the clinical significance of some recent work. This is followed by a section on the systemic use of the agent, both alone and in combination with other cancer chemotherapeutic agents; there are included sections on the infusion use of methotrexate and the intrathecal use in acute leukemia involving the central nervous system. The material presented is a very worthwhile addition to the library of those interested in cancer chemotherapy. In particular, the discussion section following each major group of papers is very worthwhile, as it presents the review of many experts in these fields. The papers are fully reproduced with colored or black-and-white photographs, as well as charts. This symposium adequately points out


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.